Datasheet

HIV-1 p24 Antibody
CATALOG NUMBER: 7313

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Virus
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:P24 antibody can be used for detection of p24 by Western blot at 0.5 - 1 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 95-153 - HIV-1 p24 Recombinant Protein
PREDICTED MOLECULAR WEIGHT:24 kDa
SPECIFICITY:P24 antibody detects a 24 kDa recombinant protein.
IMMUNOGEN:Rabbit polyclonal HIV-1 p24 antibody was raised against a recombinant full-length HIV-1 p24 protein .
HOST SPECIES:Rabbit

Properties

PURIFICATION:HIV-1 p24 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:HIV-1 p24 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:HIV-1 p24 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:HIV-1 p24 Antibody: Gag polyprotein, Pr55Gag, MA
ACCESSION NO.:AAB50258
PROTEIN GI NO.:327745
OFFICIAL SYMBOL:GAG
GENE ID:155030

Background

BACKGROUND:HIV-1 p24 Antibody: The human immunodeficiency virus type 1 (HIV-1) particle consists of an envelope, a core and the region between the two termed matrix. The HIV-1 Gag protein is a late structural protein that contains four proteins: matrix (p17), capsid (p24), nucleocapsid (p7) and the p6 protein. The p24 is the major capsid protein of the virus and has been used in clinical trials as one of the components of the HIV-1 vaccine because of the high degree of sequence conservation between different strains.
REFERENCES: 1) Goto T, Nakai M, and Ikuta K. The life-cycle of human immunodeficiency virus type 1. Micron 1998; 29:123-38.
2) Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998; 251:1-15.
3) Lindenburg CE, Stolte I, Langendam MW, et al. Long-term follow-up : no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine 2002 ; 20 :2343-7.

For Research Use Only